Dr. Kauff Discusses Remaining Questions in the Treatment of Patients With Uterine Cancer

TORL-1-23 was well tolerated and showed efficacy in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free and overall survival rates vs those given olaparib alone.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.